Navigation Links
New screening strategy may catch ovarian cancer at early stages
Date:8/25/2013

A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy is described in a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. If verified in an ongoing clinical trial, it could potentially help save the lives of thousands of women each year in the United States alone.

There currently are no established screening strategies for ovarian cancer. The disease often causes no specific symptoms and is difficult to detect in the early stages when it is most responsive to treatment. Therefore, ovarian cancer is highly lethal because most women have advanced disease when they are diagnosed.

Karen Lu, MD, of The University of Texas MD Anderson Cancer Center in Houston, led a team that tested the potential of a two-stage ovarian cancer screening strategy that incorporates changes in a blood protein called CA125, which is a known tumor marker. In their 11-year study, 4051 post- menopausal women initially underwent an annual CA125 blood test. Based on a calculation called the "Risk of Ovarian Cancer Algorithm," women were divided into three groups: those who should receive another CA125 test one year later (low risk), those who should receive a repeat CA125 in three months (intermediate risk), and those who should receive a transvaginal ultrasound and be referred to a gynecologic oncologist (high risk).

An average of 5.8 percent of women were found to be of intermediate risk each year, meaning that they should receive a CA125 test in three months. The average annual referral rate to transvaginal ultrasound and review by a gynecologic oncologist was 0.9 percent. Ten women underwent surgery based on their ultrasound exams, with four having invasive ovarian cancers, two having ovarian tumors of low malignant potential, one having endometrial cancer, and three having benign ovarian tumors. This equates to a positive predictive value of 40 percent for detecting invasive ovarian cancer. The specificity of the testing strategy was 99.9 percent, meaning that only 0.1 percent of patients without cancer would be falsely identified as having the disease. Importantly, all of the ovarian cancers were early stage.

The findings indicate that this screening strategy achieves high specificity with very few false positive results in post-menopausal women. "The results from our study are not practice-changing at this time; however, our findings suggest that using a longitudinal (or change over time) screening strategy may be beneficial in post-menopausal women with an average risk of developing ovarian cancer," said Dr. Lu. "We are currently waiting for the results of a larger, randomized study currently being conducted in the United Kingdom that uses the same Risk of Ovarian Cancer Algorithm in a similar population of women. If the results of this study are also positive, then this will result in a change in practice."


'/>"/>

Contact: Amy Molnar
sciencenewsroom@wiley.com
Wiley
Source:Eurekalert

Related medicine news :

1. CA-125 change over time shows promise as screening tool for early detection of ovarian cancer
2. Prostate cancer screening: New data support watchful waiting
3. Onsite colposcopy clinic improves cancer screening rates: Study
4. Colorectal Cancer (CRC) Screening Market for Diagnosis & Treatment 2018 Forecasts in New Research Report at RnRMarketResearch.com
5. Volumetric Breast Density Software Improves the Accuracy in Calculation of Patient-Specific Mean Glandular Dose (MGD) in Breast Screening
6. Effect of mailed outreach invitations to underserved patients for colorectal cancer screening
7. Trial finds more support for universal HIV screening in emergency departments
8. Tomosynthesis reduces breast cancer screening recall rate
9. RSNA: Tomosynthesis Reduces Breast Cancer Screening Recall Rate
10. Decision aids associated with increase in informed decision making about prostate cancer screening
11. Daon Trusted Identity Services Expands Background Screening Services to 80 Locations Across Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... ... ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on to support ... author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, his ... of age, he joined the Navy and got married right out of boot camp. ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that ... of published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose ... since high school and have many different titles,” Gaapf mentions about his different works. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear for ... games that circumvent health needs of over 30 million. Many interviews with Dr. Carol ... needs government public servants were suppose to prioritize. Interviews provided below. , ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017 Stock-Callers.com today evaluates the following ... ), Novo Nordisk A/S (NYSE: NVO ), Sucampo ... Holdings Inc. (NASDAQ: PTX ). These stocks belong ... th , 2017, finishing near its session lows. As per ... 0.7%, while shares of health care companies in the S&P ...
(Date:1/20/2017)... LONDON , January 20, 2017 Avillion ... the appointment of Mark Weinberg , MD MBA as Chief ... , USA . ... Dr Weinberg has spent more than 17 ... "top 20" pharma companies to micro-cap biotech. Over the course of ...
(Date:1/19/2017)... 19, 2017 The U.S. Food and Drug Administration ... Constipation (CIC) in adult patients. "No one ... said Julie Beitz , M.D., director of the Office ... Evaluation and Research. "With the availability of new therapies, patients ... their condition." ...
Breaking Medicine Technology: